Oncology Unplugged With Dr Chandler Park

ADCs, and Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

ByChandler Park, MD, MSc, FACP,Neil Iyengar, MD

June 12th 2026

Drs Park and Iyengar discuss the evolving treatment paradigm for TNBC, the integration of metabolic health strategies, and the clinical emergence of ADCs.

HIF-2 Targeting Is Set to Transform Kidney Cancer Management: With Chandler Park, MD; and Katy Beckermann, MD

ByChandler Park, MD, MSc, FACP,Kathryn E. Beckermann, MD, PhD

March 31st 2026

Drs Park and Beckermann discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium.

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Midhun Malla, MD, the University of Alabama at Birmingham

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

ByChandler Park, MD, MSc, FACP,Midhun Malla, MD

July 2nd 2025

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD

ByChandler Park, MD, MSc, FACP,Midhun Malla, MD

June 26th 2025

Chandler Park, MD and Midhun Malla, MD discuss treatment personalization in mCRC, with a focus on BRAF V600E–mutant tumors and HER2-altered disease.

Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD

ByChandler Park, MD, MSc, FACP,Midhun Malla, MD

May 29th 2025

Park and Malla discuss evolving approaches to colorectal cancer (CRC) management, with a focus on ctDNA, adjuvant therapy decision-making, and molecular profiling in metastatic disease.

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Paul Hanona, MD, content creator, @doctordiscover

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

ByChandler Park, MD, MSc, FACP,Paul Hanona, MD

May 26th 2025

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Paul Hanona, MD, chief Hematology Oncology Fellow, Beaumont Health

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

ByChandler Park, MD, MSc, FACP,Paul Hanona, MD

April 21st 2025

In this episode, Drs Park and Hanona give advice to up-and-coming oncology content creators.

Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD

ByChandler Park, MD, MSc, FACP,Paul Hanona, MD

April 16th 2025

Drs Park and Hanona discuss the role of social media in educating patients and oncologists about treatment advances and novel cancer screening methods.

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Vadim Koshkin, MD, associate professor, medicine, Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco (UCSF) School of Medicine, genitourinary medical oncologist, UCSF Helen Diller Comprehensive Cancer Center

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

ByChandler Park, MD, MSc, FACP,Vadim S. Koshkin, MD

April 14th 2025

Drs Park and Koshkin explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer.

Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD

ByChandler Park, MD, MSc, FACP,Vadim S. Koshkin, MD

April 9th 2025

Drs Park and Koshkin discuss sequencing antibody-drug conjugates for bladder cancer and the potential future role of sacituzimab govitecan in this disease.

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

ByChandler Park, MD, MSc, FACP,Vadim S. Koshkin, MD

April 2nd 2025

Drs Park and Koshkin discuss the benefits of enfortumab vedotin in bladder cancer and the potential for more ADCs to join the treatment paradigm.

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Ann S. LaCasce, MD, MMSc, associate professor, medicine, lymphoma specialist, Dana-Farber Cancer Institute, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

ByChandler Park, MD, MSc, FACP,Ann S. LaCasce, MD, MMSc

March 26th 2025

Drs Park and LaCasce discuss advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity.

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

ByChandler Park, MD, MSc, FACP,Petros Grivas MD, PhD

March 12th 2025

Drs. Grivas and Park discuss developments in bladder cancer research, including the potential of HER2-targeted therapies and PD-1/PD-L1 inhibitors in the neoadjuvant setting.

Oncology Unplugged With Dr Chandler Park

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

ByChandler Park, MD, MSc, FACP,Petros Grivas MD, PhD,Ruben Raychaudhuri, MD

February 26th 2025

Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

ByChandler Park, MD, MSc, FACP,Yan Leyfman, MD

January 15th 2025

Drs Park and Leyfman discuss their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD

ByChandler Park, MD, MSc, FACP,Joshua Brody, MD, of Mount Sinai Hospital

January 8th 2025

Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like Burkitt lymphoma.

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

ByChandler Park, MD, MSc, FACP,Stephen Liu, MD

December 11th 2024

Drs Park and Liu discuss the use of amivantamab plus lazertinib in EGFR-mutated non–small cell lung cancer.

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD

ByChandler Park, MD, MSc, FACP,Stephen Liu, MD

November 27th 2024

Hear Chandler Park, MD and Stephen Liu, MD, explore advancements in EGFR-mutated NSCLC treatment, including TKI strategies, emerging therapies prioritizing a patient-centric approach.

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

ByChandler Park, MD, MSc, FACP

November 6th 2024

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

ByChandler Park, MD, MSc, FACP,Vivek Subbiah, MD

October 30th 2024

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

ByChandler Park, MD, MSc, FACP,Tejas Patil, MD

October 16th 2024

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD

ByChandler Park, MD, MSc, FACP,Tejas Patil, MD

October 2nd 2024

Drs Park and Patil discuss the evolving small cell lung cancer treatment paradigm, focusing on PCI, immune checkpoint inhibitors, and recent study data.

Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024

ByChandler Park, MD, MSc, FACP,Tejas Patil, MD

September 18th 2024

In this episode, Drs Park and Patil discuss key updates from the 2024 ASCO Annual Meeting, including the significance of data from the phase 3 LAURA trial.

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

ByChandler Park, MD, MSc, FACP,Stephanie L. Graff, MD, FACP

September 4th 2024

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

ByChandler Park, MD, MSc, FACP,Pashtoon M. Kasi, MD, MS

August 21st 2024

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Park and Grivas Expand on Treatment Updates in Bladder Cancer

ByChandler Park, MD, MSc, FACP,Petros Grivas MD, PhD

August 7th 2024

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

ByChandler Park, MD, MSc, FACP,Guru Sonpavde, MD

July 24th 2024

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

ByChandler Park, MD, MSc, FACP,Guru Sonpavde, MD

July 10th 2024

Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

ByChandler Park, MD, MSc, FACP,Guru Sonpavde, MD

May 30th 2024

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial of enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Oncology Unplugged With Dr Chandler Park

ADCs, and Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

HIF-2 Targeting Is Set to Transform Kidney Cancer Management: With Chandler Park, MD; and Katy Beckermann, MD

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD

Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD

Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Trending on OncLive

FDA Grants Full Approval to Afami-Cel for Advanced Synovial Sarcoma

Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL

Dose-Modified, Fixed-Duration Ibrutinib Plus Venetoclax Meets ORR End Point in Untreated CLL

Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC

Sacituzumab Govitecan Approved in Europe for First-Line PD-L1 Inhibitor–Ineligible TNBC